Abstract

Aim: We aimed to determine the safety and efficacy of insulin glargine(Lantus®) in Type 1 diabetic patients and to present our country's data on this issue.

Material and Methods: Retrospective chart analysis is performed on 25 Type 1 diabetic patients (12 male, 13 female) 6 months after switching to insulin glargine (IG) therapy.

Results: Mean HbA c levels before and after IG therapy were 9.2±1.7 % and 8.1±1.4% respectively (p<0,05). Eighteen patients' response (% 72) were a decrease in HbA c levels by 1.8±1.1%; whereas the remaining 7 patients' response to insulin glargine therapy were a rise of 0.6±0.5 %. When the number of hypoglycemic episodes were analysed; we observed that there were no statistically significiant difference in nocturnal hypoglycemic episodes but severe hypoglycemic episodes (% 65) decreased from 7.7±7.3 to 5.5±6.9 episodes/month (p<0,05).

Conclusion: Insulin glargine treatment improved gylcemic control in children and adolescents with type 1 diabetes without increasing hypoglycemic episodes

Keywords: Type 1 diabetes, insulin glargine, hypoglycemia

References

  1. Alemzadeh R, Behre T, Wyatt DT. Flexible insulin theraphy with insu- lin glargine improved glycemic control and reduced severe hypo- glycemia among preschool-aged children with type 1 diabetes melli- tus. Pediatrics 2005;115:1320-1324.
  2. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999;22:109-113.
  3. Witthaus E, Stewart J, Bradley C. Treatment statisfaction and psycho- logical well-being with insulin glargine compared with NPH in pati- ents with type 1 diabetes. Diabetes Med 2001;18:619-625.
  4. Heise T, Bott S, Rave K,Dressler A, Rosskamp R, Heinemann L. No
  5. evidence for accumulation of insulin glargine (Lantus) a multiple in- jection study in patients with type 1 diabetes. Diabetes Med 2002; 19:490-495.
  6. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A rando Kaplan W, Rodriquez LM, Smith OE, Haymond MW, Heptulla RA.
  7. Effects of mixing glargine and short acting insulin anologes on gluco Jackson A, Ternand C, Brunzell C, Kleinschmidt T, Dew D, Milla C,
  8. Moran A. Insulin glargine improves hemoglobin A1c in children and adolescents with poorly controlled type 1 diabetes. Pediatr Diabetes 2003;4:64-69.
  9. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlack M, Heise T. Time action profile of the long-acting insulin glargine in compa- rison withthose of NPH insulin and placebo. Diabetes Care 2000; 23:644-649.
  10. Colino E, Lopez-Capape M, Golmayo L, Alvarez MA, Alonso M, Barrio R. Therapy with insulin glargine (Lantus) in toddlers, children
  11. Schober E, Schoenle E, Van Dyk 1, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adoLepore M, Pampenelli S, Fanelli C ,Porcellati F, Bartocci I,
  12. DiVincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Matyka K, Wigg L, Pramming S, Dunger DB. Cognitive function and mood after profound nocturnal hypoglycemia in prepubertal children Libman IM, Pietropaolo M, Arlanian SA, Laporte RE, Becker DJ. C
  13. hanging prevelance of overweight children and adolescents at onset of insulin treated diabetes. Diabetes 2003;26:2871-2875.

Copyright and license

How to cite

1.
Çetinkaya E, Kibar AE, Aycan Z, Vidinlisan S, Çakır B, Gökdağ B, et al. TİP 1 DİABETES MELLİTUS’TA İNSULİN GLARGİN TEDAVİSİNE GEÇİŞİN HİPOGLİSEMİK ATAKLARA ve HEMOGLOBİN A C DÜZEYLERİNE ETKİSİ. Turk J Pediatr Dis [Internet]. 2008 Jun. 1 [cited 2025 May 24];2(2):5-10. Available from: https://turkjpediatrdis.org/article/view/30